Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects.
European archives of psychiatry and clinical neuroscience June 1, 2026 Ziping He, Yijie Wang, Jiemin Chen et al. 1 citation
A review of seven trials involving 464 adults with major depressive disorder found that psilocybin significantly reduces depression symptoms and is generally safe and tolerable. Higher doses (35–50 mg per 70 kg of body weight) and a double-dosing schedule were associated with better outcomes. The overall quality of the trials was moderate, and the authors note that the results are limited by small sample sizes and short follow-up periods, indicating a need for further research.